Cerevel Therapeutics Holdings, Inc. (CERE)

NASDAQ: CERE · IEX Real-Time Price · USD
34.15
-0.40 (-1.16%)
Jan 31, 2023, 4:00 PM EST - Market closed
-1.16%
Market Cap 5.34B
Revenue (ttm) n/a
Net Income (ttm) -317.76M
Shares Out 156.32M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 510,718
Open 34.54
Previous Close 34.55
Day's Range 34.05 - 35.26
52-Week Range 19.86 - 41.46
Beta 1.47
Analysts Buy
Price Target 41.63 (+21.9%)
Earnings Date Feb 27, 2023

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a sel... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 285
Stock Exchange NASDAQ
Ticker Symbol CERE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for CERE stock is "Buy." The 12-month stock price forecast is $41.63, which is an increase of 21.90% from the latest price.

Price Target
$41.63
(21.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

11 minutes ago - GlobeNewsWire

Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indication as a once-daily treatment

3 weeks ago - GlobeNewsWire

Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced t...

1 month ago - GlobeNewsWire

Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial

Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia

1 month ago - GlobeNewsWire

Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia

Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration

1 month ago - GlobeNewsWire

Cerevel Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that me...

2 months ago - GlobeNewsWire

Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline

3 months ago - GlobeNewsWire

Why Cerevel Therapeutics (CERE) Might Surprise This Earnings Season

Cerevel Therapeutics (CERE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 months ago - Zacks Investment Research

Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

3 months ago - GlobeNewsWire

Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that m...

5 months ago - GlobeNewsWire

Cerevel Therapeutics Stock Is Falling: Here's Why

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 7.1% to $32.00 during Tuesday's trading session after the company priced its underwritten common stock offering of 7.25 mil...

6 months ago - Benzinga

Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024

6 months ago - GlobeNewsWire

Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022

CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

6 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today th...

8 months ago - GlobeNewsWire

Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chai...

9 months ago - GlobeNewsWire

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022

9 months ago - GlobeNewsWire

Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced i...

10 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022

Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy

10 months ago - GlobeNewsWire

Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that ch...

11 months ago - GlobeNewsWire

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results

Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety

1 year ago - GlobeNewsWire

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

1 year ago - GlobeNewsWire